Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
66.20    -1.80 (-2.65%)
Bid:
65.90
Ask:
66.70
Spread: 0.80 (1.214%)
Market Cap: £584.83m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Result of AGM

12 Jun 2025 12:54

RNS Number : 6278M
IP Group PLC
12 June 2025
 

 

FOR RELEASE ON

12 June 2025

 

IP Group plc - Results of Annual General Meeting

 

The Annual General Meeting ("AGM") of IP Group plc was held earlier today. All of the Resolutions proposed at the AGM were passed by the appropriate majority on a poll.

 

IP Group plc Annual General Meeting Poll Results

 

RESOLUTION

VOTESFOR

%

VOTESAGAINST

%

VOTESTOTAL

% of ISC VOTED

VOTESWITHHELD

1

To receive the Directors' Report, the Audited Statement of Accounts and Auditor's Report of the Company for the financial year ended 31 December 2024.

638,069,760

99.97%

172,761

0.03%

638,242,521

68.97%

1,106,160

2

To approve the Directors' Remuneration Report for the year ended 31 December 2024.

547,362,600

85.69%

91,428,282

14.31%

638,790,882

69.03%

557,799

3

To approve the Directors' Remuneration Policy.

601,336,021

94.56%

34,602,374

5.44%

635,938,395

68.72%

3,410,286

4

To re-appoint KPMG LLP as auditor of the Company.

636,677,576

99.67%

2,118,153

0.33%

638,795,729

69.03%

552,952

5

To authorise the Directors to fix the remuneration of KPMG LLP as auditor of the Company.

638,578,984

99.96%

230,752

0.04%

638,809,736

69.03%

538,945

6

To re-elect Mr David Baynes as a Director of the Company.

638,234,627

99.92%

532,459

0.08%

638,767,086

69.02%

581,595

7

To re-elect Dr Caroline Brown as a Director of the Company.

630,396,363

98.69%

8,392,053

1.31%

638,788,416

69.03%

560,265

8

To re-elect Mr Heejae Chae as a Director of the Company.

521,236,223

81.60%

117,550,713

18.40%

638,786,936

69.03%

561,745

9

To re-elect Sir Douglas Flint as a Director of the Company.

622,456,601

97.44%

16,329,835

2.56%

638,786,436

69.03%

562,245

10

To re-elect Ms Aedhmar Hynes as a Director of the Company.

631,137,324

98.80%

7,651,092

1.20%

638,788,416

69.03%

560,265

11

To re-elect Ms Anita Kidgell as a Director of the Company.

631,693,594

98.89%

7,091,189

1.11%

638,784,783

69.02%

563,898

12

To re-elect Mr Greg Smith as a Director of the Company.

638,049,470

99.89%

717,616

0.11%

638,767,086

69.02%

581,595

13

To authorise the Directors to exercise all the powers of the Company to allot shares and grant rights to subscribe for or to convert any security into shares in the Company subject to the limits set out in the AGM notice.

631,629,282

98.87%

7,200,484

1.13%

638,829,766

69.03%

518,915

14

To empower the Directors to allot equity securities for cash, or sell treasury shares, dis-applying statutory pre-emption rights subject to the limits set out in the AGM notice.

626,369,368

98.40%

10,215,247

1.60%

636,584,615

68.79%

2,764,066

15

In addition to the authority granted under Resolution 14, to empower the Directors to allot equity securities in connection with an acquisition or other capital investment as if section 561(1) of the Companies Act 2006 ("Act") did not apply to any such allotment, subject to the limits set out in the AGM notice.

625,506,262

98.26%

11,072,605

1.74%

636,578,867

68.79%

2,769,814

16

To authorise the Company and its subsidiaries to incur political expenditure (as defined in section 365 of the Act) not exceeding £50,000 in total.

628,921,989

99.81%

1,201,783

0.19%

630,123,772

68.09%

9,224,909

17

To authorise the Company to make market purchases (as defined in section 693(4) of the Act) of the Company's ordinary shares, subject to the limits set out in the AGM notice.

635,552,056

99.51%

3,160,430

0.49%

638,712,486

69.02%

636,195

18

To enable a general meeting other than an Annual General Meeting to be called on not less than 14 clear days' notice.

607,377,465

95.08%

31,446,968

4.92%

638,824,433

69.03%

524,248

 

 

 

In accordance with Listing Rule 9.6.1, a copy of the Resolutions has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism.

 

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7979 853802

 

Portland

Alex Donaldson

+44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science investor, we develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutionsOur specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFLLFFEQLEBBL
Date   Source Headline
3rd Jun 20267:00 amRNSHolding(s) in Company
2nd Jun 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
28th May 20267:00 amRNSHolding(s) in Company
13th May 20265:30 pmRNSNotice of AGM
12th May 20269:10 amRNS-REnterprise reports positive results from P2 trial
11th May 20264:25 pmRNSHolding(s) in Company
11th May 20264:19 pmRNSHolding(s) in Company
7th May 20267:00 amRNSAppointment of Chair Designate
23rd Apr 202612:18 pmRNSDirector/PDMR Shareholding
21st Apr 20267:00 amRNS-RFirst Light announces £25m successful first close
15th Apr 20265:00 pmRNSAnnual Financial Report
14th Apr 20269:25 amRNSHolding(s) in Company
30th Mar 20262:00 pmRNSNew climate fund launch with Australia's CEFC
26th Mar 202610:00 amRNSHolding(s) in Company
25th Mar 20262:00 pmRNSHolding(s) in Company
19th Mar 20265:30 pmRNSHolding(s) in Company
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
13th Mar 20265:45 pmRNSHolding(s) in Company
12th Mar 202611:00 amRNSHolding(s) in Company
12th Mar 20269:00 amRNSNotice of Results
12th Mar 20269:00 amRNSNotice of Results
4th Mar 20267:00 amRNS-RPortfolio company Oxa raises $103m in Series D
26th Feb 20262:53 pmRNSHolding(s) in Company
26th Feb 20269:30 amRNSHolding(s) in Company
25th Feb 20265:51 pmRNSHolding(s) in Company
11th Feb 20269:01 amRNS-RMicrobiotica announces positive P1b trial results
30th Jan 20267:00 amRNSHolding(s) in Company
29th Jan 20267:00 amRNSHolding(s) in Company
20th Jan 202612:36 pmRNSHolding(s) in Company
14th Jan 20267:00 amRNSDirectorate change
14th Jan 20267:00 amRNSHolding(s) in Company
12th Jan 20266:25 pmRNSHolding(s) in Company
7th Jan 20262:06 pmRNSPulmocide announces termination of Phase 3 study
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNSHolding(s) in Company
5th Dec 20255:26 pmRNSHolding(s) in Company
4th Dec 20254:13 pmRNSHolding(s) in Company
1st Dec 20255:37 pmRNSTotal Voting Rights
20th Nov 20257:00 amRNSCompletion of share buyback programme
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
17th Nov 20251:10 pmRNSArtios completes oversubscribed $115m financing
14th Nov 20255:47 pmRNSTransaction in Own Shares
14th Nov 20258:20 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.